1. Home
  2. STTK vs EVEX Comparison

STTK vs EVEX Comparison

Compare STTK & EVEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.85

Market Cap

792.9M

Sector

Health Care

ML Signal

HOLD

Logo Eve Holding Inc.

EVEX

Eve Holding Inc.

HOLD

Current Price

$2.23

Market Cap

888.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
EVEX
Founded
2016
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
792.9M
888.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
STTK
EVEX
Price
$6.85
$2.23
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$10.00
$6.88
AVG Volume (30 Days)
773.5K
806.9K
Earning Date
05-01-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11,676.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.59
$2.10
52 Week High
$8.33
$5.16

Technical Indicators

Market Signals
Indicator
STTK
EVEX
Relative Strength Index (RSI) 44.39 36.95
Support Level $5.87 $2.15
Resistance Level $7.75 $2.81
Average True Range (ATR) 0.34 0.13
MACD -0.12 -0.05
Stochastic Oscillator 11.51 16.25

Price Performance

Historical Comparison
STTK
EVEX

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About EVEX Eve Holding Inc.

Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.

Share on Social Networks: